Evidence map›Paper›PMID 19608354›Full record

Trial reportDrug and alcohol dependence2009

Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables.

Andy C Dean, Edythe D London, Catherine A Sugar, Christina M R Kitchen, Aimee-Noelle Swanson, Keith G Heinzerling, Ari D Kalechstein, Steven Shoptaw

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Drug and alcohol dependence, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Efficacy of psychostimulant drugs for amphetamine abuse or dependence.The Cochrane database of systematic reviews · 2013
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Boundary conditions of methamphetamine craving.Experimental and clinical psychopharmacology · 2015
    Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Andy C DeanDepartment of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute, 760 Westwood Plaza, Box 951759, Los Angeles, CA 90095, USA. acdean@mednet.ucla.edu
Edythe D London
Catherine A Sugar
Christina M R Kitchen
Aimee-Noelle Swanson
Keith G Heinzerling
Ari D Kalechstein
Steven Shoptaw
University of California, Los Angeles · USNeurobehavioral Systems · US

Funding

UCLA Medication Development Unit for Stimulant AbuseP50DA018185 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHOPTAW, STEVEN J · 2004 to 2009
$5.8M
NEUROCHEMISTRY OF MODAFINIL-MA INTERACTION IN RAT BRAINP20DA022539 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LONDON, EDYTHE DANICK · 2006 to 2009
$2.9M
NIDA NIH HHS 1 P50 - DA 18185NIDA NIH HHS P20 DA022539NIDA NIH HHS P20 - DA022539NIDA NIH HHS P50 DA018185
6 · The paper itself

Abstract

Although some individuals who abuse methamphetamine have considerable cognitive deficits, no prior studies have examined whether neurocognitive functioning is associated with outcome of treatment for methamphetamine dependence. In an outpatient clinical trial of bupropion combined with cognitive behavioral therapy and contingency management (Shoptaw, S., Heinzerling, K.G., Rotheram-Fuller, E., Steward, T., Wang, J., Swanson, A.N., De La Garza, R., Newton, T., Ling, W., 2008. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend 96, 222-232.), 60 methamphetamine-dependent adults completed three tests of reaction time and working memory at baseline. Other variables that were collected at baseline included measures of drug use, mood/psychiatric functioning, employment, social context, legal status, and medical status. We evaluated the relative predictive value of all baseline measures for treatment outcome using Classification and Regression Trees (CART; Breiman, L., Friedman, J.H., Olshen, R.A., Stone, C.J., 1984. Classification and Regression Trees. Wadsworth, Belmont, CA.), a nonparametric statistical technique that produces easily interpretable decision rules for classifying subjects that are particularly useful in clinical settings. Outcome measures were whether or not a participant completed the trial and whether or not most urine tests showed abstinence from methamphetamine abuse. Urine-verified methamphetamine abuse at the beginning of the study was the strongest predictor of treatment outcome; two psychosocial measures (e.g., nicotine dependence and Global Assessment of Functioning) also offered some predictive value. A few reaction time and working memory variables were related to treatment outcome, but these cognitive measures did not significantly aid prediction after adjusting for methamphetamine usage at the beginning of the study. On the basis of these findings, we recommend that research groups seeking to identify new predictors of treatment outcome compare the predictors to methamphetamine usage variables to assure that unique predictive power is attained.

Indexed as

MethamphetaminePatient ComplianceAdultAffectAmphetamine-Related DisordersAnalysis of VarianceAntidepressive Agents, Second-GenerationBupropionCognitive Behavioral TherapyCrimeFemaleHumansMaleMemory, Short-TermNeuropsychological TestsPredictive Value of TestsAntidepressive Agents, Second-GenerationBupropionMethamphetamine

Identifiers

PMID19608354
PMCPMC2754143
OpenAlexW2082216143

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.